Solventum (SOLV) is acquiring Acera Surgical, a bioscience firm focused on synthetic tissue matrices for wound care, for $725M in cash plus up to $125M in milestones. The move boosts Solventum’s MedSurg portfolio, especially in the fast-growing regenerative wound care market. Acera’s Restrata products will complement Solventum’s negative pressure wound therapy, aiming to accelerate adoption in acute care. The deal is expected to close in the first half of 2026. It's projected to be slightly EPS dilutive in 2026 and accretive from 2027 onward. No new debt will be used for the purchase.